TY - JOUR
T1 - When to Start Antiretroviral Therapy in Children Aged 2-5 Years
T2 - A Collaborative Causal Modelling Analysis of Cohort Studies from Southern Africa
AU - Schomaker, Michael
AU - Egger, Matthias
AU - Ndirangu, James
AU - Phiri, Sam
AU - Moultrie, Harry
AU - Technau, Karl
AU - Cox, Vivian
AU - Giddy, Janet
AU - Chimbetete, Cleophas
AU - Wood, Robin
AU - Gsponer, Thomas
AU - Bolton Moore, Carolyn
AU - Rabie, Helena
AU - Eley, Brian
AU - Muhe, Lulu
AU - Penazzato, Martina
AU - Essajee, Shaffiq
AU - Keiser, Olivia
AU - Davies, Mary Ann
AU - Ndirangu, James
AU - Hoffmann, Christopher
AU - Chi, Benjamin
AU - Naniche, Denise
AU - Wood, Robin
AU - Dickinson, Diana
AU - Stinson, Kathryn
AU - Fatti, Geoffrey
AU - Phiri, Sam
AU - Giddy, Janet
AU - Wellington, Maureen
AU - Malisita, Kennedy
AU - Eley, Brian
AU - Llenas, Jara
AU - Fritz, Christiane
AU - Fox, Matthew
AU - Maskew, Mhairi
AU - Prozesky, Hans
AU - Technau, Karl
AU - Moultrie, Harry
PY - 2013/11
Y1 - 2013/11
N2 - Background:There is limited evidence on the optimal timing of antiretroviral therapy (ART) initiation in children 2-5 y of age. We conducted a causal modelling analysis using the International Epidemiologic Databases to Evaluate AIDS-Southern Africa (IeDEA-SA) collaborative dataset to determine the difference in mortality when starting ART in children aged 2-5 y immediately (irrespective of CD4 criteria), as recommended in the World Health Organization (WHO) 2013 guidelines, compared to deferring to lower CD4 thresholds, for example, the WHO 2010 recommended threshold of CD4 count <750 cells/mm3 or CD4 percentage (CD4%) <25%.Methods and Findings:ART-naïve children enrolling in HIV care at IeDEA-SA sites who were between 24 and 59 mo of age at first visit and with ≥1 visit prior to ART initiation and ≥1 follow-up visit were included. We estimated mortality for ART initiation at different CD4 thresholds for up to 3 y using g-computation, adjusting for measured time-dependent confounding of CD4 percent, CD4 count, and weight-for-age z-score. Confidence intervals were constructed using bootstrapping.The median (first; third quartile) age at first visit of 2,934 children (51% male) included in the analysis was 3.3 y (2.6; 4.1), with a median (first; third quartile) CD4 count of 592 cells/mm3 (356; 895) and median (first; third quartile) CD4% of 16% (10%; 23%). The estimated cumulative mortality after 3 y for ART initiation at different CD4 thresholds ranged from 3.4% (95% CI: 2.1-6.5) (no ART) to 2.1% (95% CI: 1.3%-3.5%) (ART irrespective of CD4 value). Estimated mortality was overall higher when initiating ART at lower CD4 values or not at all. There was no mortality difference between starting ART immediately, irrespective of CD4 value, and ART initiation at the WHO 2010 recommended threshold of CD4 count <750 cells/mm3 or CD4% <25%, with mortality estimates of 2.1% (95% CI: 1.3%-3.5%) and 2.2% (95% CI: 1.4%-3.5%) after 3 y, respectively. The analysis was limited by loss to follow-up and the unavailability of WHO staging data.Conclusions:The results indicate no mortality difference for up to 3 y between ART initiation irrespective of CD4 value and ART initiation at a threshold of CD4 count <750 cells/mm3 or CD4% <25%, but there are overall higher point estimates for mortality when ART is initiated at lower CD4 values.Please see later in the article for the Editors' Summary.
AB - Background:There is limited evidence on the optimal timing of antiretroviral therapy (ART) initiation in children 2-5 y of age. We conducted a causal modelling analysis using the International Epidemiologic Databases to Evaluate AIDS-Southern Africa (IeDEA-SA) collaborative dataset to determine the difference in mortality when starting ART in children aged 2-5 y immediately (irrespective of CD4 criteria), as recommended in the World Health Organization (WHO) 2013 guidelines, compared to deferring to lower CD4 thresholds, for example, the WHO 2010 recommended threshold of CD4 count <750 cells/mm3 or CD4 percentage (CD4%) <25%.Methods and Findings:ART-naïve children enrolling in HIV care at IeDEA-SA sites who were between 24 and 59 mo of age at first visit and with ≥1 visit prior to ART initiation and ≥1 follow-up visit were included. We estimated mortality for ART initiation at different CD4 thresholds for up to 3 y using g-computation, adjusting for measured time-dependent confounding of CD4 percent, CD4 count, and weight-for-age z-score. Confidence intervals were constructed using bootstrapping.The median (first; third quartile) age at first visit of 2,934 children (51% male) included in the analysis was 3.3 y (2.6; 4.1), with a median (first; third quartile) CD4 count of 592 cells/mm3 (356; 895) and median (first; third quartile) CD4% of 16% (10%; 23%). The estimated cumulative mortality after 3 y for ART initiation at different CD4 thresholds ranged from 3.4% (95% CI: 2.1-6.5) (no ART) to 2.1% (95% CI: 1.3%-3.5%) (ART irrespective of CD4 value). Estimated mortality was overall higher when initiating ART at lower CD4 values or not at all. There was no mortality difference between starting ART immediately, irrespective of CD4 value, and ART initiation at the WHO 2010 recommended threshold of CD4 count <750 cells/mm3 or CD4% <25%, with mortality estimates of 2.1% (95% CI: 1.3%-3.5%) and 2.2% (95% CI: 1.4%-3.5%) after 3 y, respectively. The analysis was limited by loss to follow-up and the unavailability of WHO staging data.Conclusions:The results indicate no mortality difference for up to 3 y between ART initiation irrespective of CD4 value and ART initiation at a threshold of CD4 count <750 cells/mm3 or CD4% <25%, but there are overall higher point estimates for mortality when ART is initiated at lower CD4 values.Please see later in the article for the Editors' Summary.
UR - http://www.scopus.com/inward/record.url?scp=84889044004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84889044004&partnerID=8YFLogxK
U2 - 10.1371/journal.pmed.1001555
DO - 10.1371/journal.pmed.1001555
M3 - Article
C2 - 24260029
AN - SCOPUS:84889044004
SN - 1549-1277
VL - 10
JO - PLoS medicine
JF - PLoS medicine
IS - 11
M1 - e1001555
ER -